Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152: A Phase 1, Double-Blind, Randomised Control Trial | Zendy

Raches Ella | Zendy; Krishna Mohan Vadrevu | Zendy; Harsh Jogdand | Zendy; Sai Prasad | Zendy; Siddharth Reddy | Zendy; Vamshi Sarangi | Zendy; Brunda Ganneru | Zendy; Gajanan Sapkal | Zendy; Pragya D. Yadav | Zendy; Priya Abraham | Zendy; Samiran Panda | Zendy; Nivedita Gupta | Zendy; Prabhakar Reddy | Zendy; Savita Verma | Zendy; Sanjay Kumar | Zendy; Chandramani Singh | Zendy; Sagar Vivek Redkar | Zendy; Chandra Sekhar Gillurkar | Zendy; Jitendra Singh Kushwaha | Zendy; Satyajit Mohapatra | Zendy; Venkat Rao | Zendy; Randeep Guleria | Zendy; Krishna M. Ella | Zendy

Open Access

Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152: A Phase 1, Double-Blind, Randomised Control Trial

Author(s) -

Raches Ella,

Krishna Mohan Vadrevu,

Harsh Jogdand,

Sai Prasad,

Siddharth Reddy,

Vamshi Sarangi,

Brunda Ganneru,

Gajanan Sapkal,

Pragya D. Yadav,

Priya Abraham,

Samiran Panda,

Nivedita Gupta,

Prabhakar Reddy,

Savita Verma,

Sanjay Kumar,

Chandramani Singh,

Sagar Vivek Redkar,

Chandra Sekhar Gillurkar,

Jitendra Singh Kushwaha,

Satyajit Mohapatra,

Venkat Rao,

Randeep Guleria,

Krishna M. Ella

Publication year - 2020

Publication title -

ssrn electronic journal

Language(s) - English

Resource type - Journals

ISSN - 1556-5068

DOI - 10.2139/ssrn.3747047

Subject(s) - immunogenicity , medicine , double blind , virology , covid-19 , clinical trial , vaccine trial , randomized controlled trial , vaccination , immunology , antibody , alternative medicine , placebo , pathology , disease , infectious disease (medical specialty)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research